Results

Most recent

AMD-Neovascular

1–10 of 220 results for AMD-Neovascular

Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results From OPTIC and LUNA Trials
Mark R. Barakat, MD
Annual Meeting Talks
2025
RO-104, a Novel Trispecific Antibody, Significantly Reduces Lesion Area and Vascular Leakage in a Laser-Induced Nonhuman Primate CNV Model
Harit K. Bhatt, MD, MBA, FASRS, FACS
Annual Meeting Talks
2025
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Annual Meeting Talks
2025
Swing vs Flick: Assessing Safer Air Bubble Removal Techniques in Intravitreal Injections
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2025
Acute Optic Nerve Anatomic Changes Following Intravitreal Injection of Pharmaceutical Agents
Sami H. Uwaydat, MD
Annual Meeting Talks
2025
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Annual Meeting Talks
2025
COAST: A Phase 3 Study of Intravitreal Sozinibercept Combined With Aflibercept in Participants With Neovascular Age-Related Macular Degeneration
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2025
Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration
Jennifer I. Lim, MD, FARVO, FASRS
Annual Meeting Talks
2025
Treatment Burden in Wet Age-Related Macular Degeneration Treated With EYP-1901 vs Aflibercept in DAVIO 2, a Phase 2 Clinical Trial
Avni P Finn, MD, MBA, FASRS
Annual Meeting Talks
2025
Efficacy and Safety of Biosimilar Aflibercept-ayyh in Clinical Use by a Consortium of Retina Practices
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2025